ArticlemicroPublication biology2025
Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.
Article in microPublication biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targeting of the G-protein coupled receptor (GPCRs) glucagon-like-peptide-1-receptor (GLP-1R) by weight loss medications has become extremely prevalent due to the effectiveness of a class of GLP-1R agonists. Also, interest in cannabinoids, such as delta-9-tetrahydrocannabinol (THC), has risen independently of GLP's newfound fame due to the relaxation of legal hurdles across the nation to recreational cannabis usage. THC interacts with receptors in the endocannabinoid system, with the major ones being cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), both GPCRs. As these GPCR targets are becoming increasingly of interest due to these independent pathways, this study aimed to identify potential crossover between the endocannabinoid system and the GLP-1R system through molecular docking experiments. This was done using endogenous (2-AG and anandamide) and exogenous (THC) ligands of the endocannabinoid system , along with a proposed small oral agonist (danuglipron) of GLP-1R. Results indicated that danuglipron, a small GLP-1R agonist, had a higher binding affinity for CB1 and CB2 than any of the endogenous or exogenous ligands of the endocannabinoid system, suggesting the potential for cross-reactivity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.